Pharma Patent Lifecycles

Patent lifecycle management is becoming more crucial for pharmaceutical companies with the cost of research and drugs continually rising and companies constantly trying to obtain the maximum financial benefit from existing patent terms. In addition to protecting existing IP rights and seeking methods to extend current patent lifecycles, pharmaceutical companies are faced with the challenge of inventing new drugs and diversifying portfolios to replace sales on older and generic drugs.

The 2011 Pharma Patent Lifecycles Forum will focus on recent cases across Europe and the US and their impact on the latest regulatory developments and strategies for patent lifecycle extensions. Our outstanding panel of experts will provide you with practical guidance on the most effective ways to successfully apply for patent term extensions and overcome the strategic challenges when dealing with the various patent offices and regulatory authorities. In addition, key regional experts will examine the current legal and regulatory processes and procedures to extend patent lifecycles in the BRIC countries, providing you with the information you need to maximise the scope of your patent portfolio.

C5’s 10th Annual Forum on Pharma Patent Lifecycles brings together eminent in-house counsel from the world’s largest pharma and biotech companies and their expert advisors from a range of jurisdictions, including the US, Europe and Asia. A special keynote address will be given by the Hon Mr. Justice Arnold on the recent cases referred to the European Court of Justice on the scope of SPCs and the impact of the pending decisions for patent lifecycle extensions. Based on their first-hand experience, the distinguished panel will provide you with invaluable information and insights on pharma patent lifecycles with a particular focus on:

• The scope of SPCs for combination products and the cases referred to the ECJ
• Adopting strategies to overcome challenges based on recent industry trends
• Employing recent cases on SPCs in Europe and the US to file successful applications
• Combating practical challenges for the grant of SPCs
• Developing strategies to successfully monitor and manage SPCs on patent portfolios
• The German Patent Offices’ perspective on tackling lifecycle extension challenges
• Examining potential anti-competitive practices and recent patent settlement agreements
• Maximising exclusivity for new medicinal products in light of regulatory and case law developments
• Extending and protecting patent lifecycles in the BRIC countries 
• Structuring successful applications for selection patents and analysing the various approaches in Europe
• Guidance from the EU Commission on lifecycle extensions
• Classifying biosimilars and follow-on biologics in Europe and the US
• Preparing for the expiration of the transitional provisions on paediatric extensions
• Successfully obtaining preliminary injunctions to block exploitation from generic drugs
• Monitoring the approval and grant processes of third party SPC applications

Be where your industry will be on 21st and 22nd June 2011 and don’t miss out on this unique opportunity to hear from and network with prominent judicial authorities, regulatory experts and industry specialists. 

Associate Sponsor:

Branding Partners:

Media Partners:

- Actions -

- Share -